{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:38:24Z","timestamp":1787740704920,"version":"build-2784847793"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Urol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Biochemical recurrence (BCR) following primary therapy for prostate cancer (PCa) is associated with disease progression; thus, identifying patients at high risk and implementing management strategies remains critical. This expert opinion outlines a set of recommendations for identifying high-risk BCR patients, provides insights into the impact of a multidisciplinary team (MDT) approach on disease management, explores associated costs and resource utilization, and examines the role of androgen receptor signaling pathway inhibitors (ARPIs) in optimizing outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The latest evidence and clinical guidelines on risk stratification, diagnostic tools, and collaborative management strategies were evaluated. Additionally, expert opinions were collected from nine oncology and urology experts, and their insights were integrated to form a comprehensive approach tailored for clinical application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The panelists reached agreement on several proposed questions, including patients\u2019 early detection, risk stratification, early management, and\u00a0the role of ARPIs and androgen deprivation therapies (ADT). The recommendations emphasize the need for standardized identification of high-risk BCR patients, treatment protocols, and early intervention strategies. Additionally, the multidisciplinary approach facilitates personalized treatment planning, leveraging various specialties\u2019 expertise, and addresses the complexity of resource utilization and cost management. However, a lack of agreement on other topics was observed, such as optimal timing of intervention and resource allocation strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This narrative, evidence-supported expert-opinion review highlights the importance of standardized protocols, multidisciplinary strategies, and the integration of advanced diagnostics and androgen receptor pathway inhibitors to improve patient outcomes. Further research is warranted to refine predictive models, optimize resource allocation, and enhance therapeutic efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fruro.2026.1719136","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:57:57Z","timestamp":1769698677000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["High-risk biochemical recurrence in prostate cancer: identification and early intervention strategies"],"prefix":"10.3389","volume":"6","author":[{"given":"Ahmed Hassan","family":"Abdelaziz","sequence":"first","affiliation":[{"name":"Ain Shams University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai Mohamed Ali","family":"Ezz El Din","sequence":"additional","affiliation":[{"name":"Ain Shams University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Hamada","sequence":"additional","affiliation":[{"name":"Cairo University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abdullah","sequence":"additional","affiliation":[{"name":"Cairo University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan Sayed","family":"Shaker","sequence":"additional","affiliation":[{"name":"Ain Shams University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Sherif","family":"Mourad","sequence":"additional","affiliation":[{"name":"Ain Shams University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Osman","sequence":"additional","affiliation":[{"name":"Ain Shams University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr Mohamed","family":"Nowier","sequence":"additional","affiliation":[{"name":"Ain Shams University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina Salah","family":"Gad","sequence":"additional","affiliation":[{"name":"Astellas","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"B2","unstructured":"Cancer today"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_351033","article-title":"Best approaches and updates for prostate cancer biochemical recurrence","author":"Simon","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.06.004","article-title":"Biochemical recurrence in prostate cancer: the european association of urology prostate cancer guidelines panel recommendations","volume":"6","author":"Van Den Broeck","year":"2020","journal-title":"Eur Urol Focus"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4103\/aja.aja_52_18","article-title":"National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: A retrospective cohort study in Chinese prostate cancer patients","volume":"20","author":"Xu","year":"2018","journal-title":"Asian J Androl"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.5489\/cuaj.5840","article-title":"Management algorithms for metastatic prostate cancer","volume":"13","author":"Malone","year":"2019","journal-title":"Can Urological Assoc J"},{"key":"B8","unstructured":"EAU guidelines on prostate cancer"},{"key":"B9","unstructured":"EUG"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann\u00a0Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Cancer Network"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00606","article-title":"Clinically localized prostate cancer: ASCO clinical practice guideline endorsement of an american urological association\/american society for radiation oncology\/society of urologic oncology guideline","volume":"36","author":"Bekelman","year":"2018","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3390\/cancers15010261","article-title":"Variables associated with false-positive PSA results: A cohort study with real-world data","volume":"15","author":"Lumbreras","year":"2022","journal-title":"Cancers"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4103\/njcp.njcp_67_22","article-title":"Correlation between prostate volume and prostate-specific antigen in Nigerian men with symptomatic histologically-diagnosed benign prostatic hyperplasia","volume":"25","author":"Aigbe","year":"2022","journal-title":"Niger J Clin Pract"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.204032","article-title":"Update on 18F-fluciclovine PET for prostate cancer imaging","volume":"59","author":"Parent","year":"2018","journal-title":"J Nucl Med"},{"key":"B18","volume-title":"Overview | Prostate cancer: diagnosis and management","year":"2021"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.09.117","article-title":"Multisite experience of the safety, detection rate and diagnostic performance of fluciclovine (18 F) positron emission tomography\/computerized tomography imaging in the staging of biochemically recurrent prostate cancer","volume":"197","author":"Bach-Gansmo","year":"2017","journal-title":"J Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.160382","article-title":"Prospective comparison of18 F-fluoromethylcholine versus68 ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy","volume":"56","author":"Morigi","year":"2015","journal-title":"J Nucl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.197160","article-title":"The impact of 68Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study","volume":"59","author":"Roach","year":"2018","journal-title":"J Nucl Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003518","article-title":"LBA02\u201309 EMBARK: A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer","volume":"210","author":"Shore","year":"2023","journal-title":"J Urol"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2025.07.023","article-title":"Re: EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer","volume-title":"Eur Urol","author":"Santiago","year":"2026"},{"key":"B25","volume-title":"Egypian Urological Guidelines Book, 2021. Committee XIV: Male Infertility","author":"Rashed","year":"2021"},{"key":"B26","unstructured":"EAU 2024: negative staging PSMA in high-risk disease: can we skip extended pelvic lymph node dissection? No, we cannot"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-024-03344-2","article-title":"The role and controversy of pelvic lymph node dissection in prostate cancer treatment: a focused review","volume":"22","author":"Dong","year":"2024","journal-title":"World J Surg Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-9056(19)34584-1","article-title":"The Phoenix criteria for biochemically recurrent prostate cancer after curative radiotherapy appear obsolete in the era of prostate-specific membrane antigen PET: A plea for urgent re-evaluation of current guidelines","volume-title":"Eur Urol Suppl","author":"Jansen","year":"2019"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000173911.82467.f9","article-title":"SALVAGE RADIATION THERAPY FOR PROSTATE SPECIFIC ANTIGEN PROGRESSION FOLLOWING RADICAL PROSTATECTOMY: 10-YEAR OUTCOME ESTIMATES","volume":"174","author":"Pazona","year":"2005","journal-title":"J Urol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000295","article-title":"Adjuvant and salvage radiotherapy after prostatectomy: Astro\/aua guideline amendment 2018-2019","volume":"202","author":"Pisansky","year":"2019","journal-title":"J Urol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"New Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.03.003","article-title":"Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study","volume":"51","author":"Garcia-Albeniz","year":"2015","journal-title":"Eur J Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"7713","DOI":"10.1038\/srep07713","article-title":"Systematic review and meta-analysis of the survival outcomes of first-line treatment options in high-risk prostate cancer","volume":"5","author":"Lei","year":"2015","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00890-4","article-title":"Salvage therapies for biochemical recurrence after definitive local treatment: a systematic review, meta-analysis, and network meta-analysis","volume":"28","author":"Matsukawa","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01\u201303 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"New Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510310","article-title":"Improved survival with enzalutamide in biochemically recurrent prostate cancer","author":"Shore","year":"2025","journal-title":"New Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.04.067","article-title":"Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction","volume":"82","author":"Nguyen","year":"2012","journal-title":"Int J Radiat OncologyBiologyPhysics"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-020-00275-3","article-title":"Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses","volume":"24","author":"Lee","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08458.x","article-title":"Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: Results of a 33-month observational study","volume":"104","author":"Spry","year":"2009","journal-title":"BJU Int"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1188\/14.ONF.21-29","article-title":"Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer","volume":"41","author":"Harrington","year":"2014","journal-title":"Oncol Nurs Forum"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29672","article-title":"Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners","volume":"121","author":"Donovan","year":"2015","journal-title":"Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2008.09.004","article-title":"Management of complications of androgen deprivation therapy in the older man","volume":"70","author":"Mohile","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/pon.4463","article-title":"Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: A controlled comparison","volume":"27","author":"Donovan","year":"2018","journal-title":"Psychooncology"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.11.023","article-title":"Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: A systematic review","volume":"69","author":"Van Den Bergh","year":"2016","journal-title":"Eur Urol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.05.007","article-title":"Association between androgen deprivation therapy and patient-reported depression in men with recurrent prostate cancer","volume":"16","author":"Thomas","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.03.055","article-title":"Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the south european uroncological group","volume":"66","author":"Da Silva","year":"2014","journal-title":"Eur Urol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.02.019","article-title":"External beam radiation therapy or brachytherapy with or without short-course neoadjuvant androgen deprivation therapy: results of a multicenter, prospective study of quality of life","volume":"98","author":"Gay","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B51","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/smrj.17","article-title":"Sexual function in elderly men receiving androgen deprivation therapy (ADT)","volume":"2","author":"Fode","year":"2014","journal-title":"Sex Med Rev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.01.078","article-title":"Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: A meta-analysis","volume":"82","author":"Tsai","year":"2013","journal-title":"Urology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2789","article-title":"1841TiP Darolutamide plus androgen-deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase III, randomized, double-blind, placebo-controlled study (ARASTEP)","volume":"34","author":"Morgans","year":"2023","journal-title":"Ann Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01157","article-title":"PRESTO: A phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J Clin Oncol"},{"key":"B57","unstructured":"ASCO GU 2024: ARASTEP: darolutamide + ADT in patients with high-risk BCR of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study"},{"key":"B58","unstructured":"Treatment intensification for high-risk biochemically recurrent M0 HSPC: EMBARK in the PSMA PET era and ongoing trials"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS243","article-title":"ARAMON: A phase 2, randomized, open-label study comparing darolutamide (DARO) vs enzalutamide (ENZA) monotherapy on serum testosterone levels in patients (pts) with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR)","volume":"42","author":"Laccetti","year":"2024","journal-title":"J Clin Oncol"},{"key":"B60","unstructured":"EAU 2024: negative staging PSMA in high-risk disease: can we skip extended pelvic lymph node dissection? No, we cannot"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp2022283287","article-title":"Comparing costs and health care resource utilization between nmHSPC and mHSPC patients: a retrospective claims analysis","volume":"28","author":"Ko","year":"2022","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21681805.2020.1851762","article-title":"Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden","volume":"55","author":"Svensson","year":"2021","journal-title":"Scand J Urol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"101729","DOI":"10.1016\/j.eclinm.2022.101729","article-title":"Cost-effectiveness of childhood cancer treatment in Egypt: Lessons to promote high-value care in a resource-limited setting based on real-world evidence","volume":"55","author":"Soliman","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B64","doi-asserted-by":"publisher","first-page":"33","DOI":"10.36401\/JQSH-22-20","article-title":"Estimation of prostate cancer cost in Egypt from a societal perspective","volume":"6","author":"Elsisi","year":"2023","journal-title":"Global J Qual Saf Healthcare"}],"container-title":["Frontiers in Urology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2026.1719136\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:57:59Z","timestamp":1769698679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fruro.2026.1719136\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":64,"alternative-id":["10.3389\/fruro.2026.1719136"],"URL":"https:\/\/doi.org\/10.3389\/fruro.2026.1719136","relation":{},"ISSN":["2673-9828"],"issn-type":[{"value":"2673-9828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"article-number":"1719136"}}